Article
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
JAMA - 4 Oct 2016
Lotta Luca A, Sharp Stephen J, Burgess Stephen, Perry John R B, Stewart Isobel D, Willems Sara M, Luan Jian'an, Ardanaz Eva, Arriola Larraitz, Balkau Beverley, Boeing Heiner, Deloukas Panos, Forouhi Nita G, Franks Paul W, Grioni Sara, Kaaks Rudolf, Key Timothy J, Navarro Carmen, Nilsson Peter M, Overvad Kim, Palli Domenico, Panico Salvatore, Quirós Jose-Ramón, Riboli Elio, Rolandsson Olov, Sacerdote Carlotta, Salamanca Elena C, Slimani Nadia, Spijkerman Annemieke Mw, Tjonneland Anne, Tumino Rosario, van der A Daphne L, van der Schouw Yvonne T, McCarthy Mark I, Barroso Inês, O'Rahilly Stephen, Savage David B, Sattar Naveed, Langenberg Claudia, Scott Robert A, Wareham Nicholas J
Abstract excerpt
Importance: Low-density lipoprotein cholesterol (LDL-C)-lowering alleles in or near NPC1L1 or HMGCR, encoding the respective molecular targets of ezetimibe and statins, have previously been used as proxies to study the efficacy of these lipid-lowering drugs. Alleles near HMGCR are associated with a higher risk of type 2 diabetes, similar to the increased incidence of new-onset diabetes associated with statin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.